Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fosmanogepix PK and Safety in Healthy Adult Chinese Subjects
NCT06961708Phase 1Completed
- Sponsor
- Basilea Pharmaceutica
- Start
- Apr 2025
- Primary completion
- Jul 2025
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of fosmanogepix in fungal infection (4 cohorts), sponsored by Basilea Pharmaceutica. Primary endpoints: Maximum Observed Plasma Concentration at 240 hours, Time to Peak Concentration at 240 hours and 4 more. Started Apr 2025; status: completed.
02
Drugs
fosmanogepix
03
Conditions
fungal infection
Beyond the preview
Go deeper on NCT06961708.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06961708.